Wilmington, Del. – September 24, 2026 -- Biophysical Therapeutics is now accepting pre-orders for an anti-aging moisturizer priced at $120, with only 500 units available in its first production run at www.IF1.skin.
The Delaware-based biotech company launched the product under a new consumer brand called IF1, named after a protein the company says plays a role in determining lifespan across mammal species.
The moisturizer's formula is based on research into why species age at different rates.
Biophysical Therapeutics says its research found that species with higher levels of IF1 protein tend to live longer -- comparing a mouse's four-year maximum lifespan to a bowhead whale's lifespan of centuries. The company reports that increasing IF1 protein in mice reduced aging as measured by a biomarker for aging.
Profits from skincare sales will help fund the company's drug pipeline.
Biophysical Therapeutics says proceeds from IF1 moisturizer sales will support its drug development programs targeting cancer, age-related diseases including Alzheimer's, and aging itself. The company holds granted patents and says it has produced experimentally-validated drugs that performed as predicted in animal testing.
The company was founded by a Cambridge-trained biochemist advised by a Harvard geneticist.
Biophysical Therapeutics was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science. The company is advised by Professor George Church of Harvard Medical School and specializes in computational biology, particularly biophysical modeling -- mathematical modeling of the physics and chemistry of biological systems, from which the company takes its name.
The anti-aging skincare market is already valued at $70 billion.
Dr. Forrest said the IF1 brand brings leading-edge anti-aging science to skincare as part of the company's broader mission to extend and improve lives at scale. Economists cited by the company estimate that slower aging could generate $38 trillion annually in economic benefit to the United States through increased life expectancy.